March 31, 2020
Paroxysmal Nocturnal Hemoglobinuria Market

Paroxysmal Nocturnal Hemoglobinuria Market To Exhibit Steady Growth Rate During The Forecast Period

Global paroxysmal nocturnal hemoglobinuria market is expected to increase from US$ 2,341.4 million in 2018 to US$ 6,203.0 million by 2027 and is expected to increase to CAGR by 11.7 per cent from 2019 to 2027.

Hematopoietic stem cells originating from the bone marrow are said to have complications such as premature red blood cell hemolysis and blood clot formation, which are the major clinical manifestations of paroxysmal nocturnal hemoglobinuria. The treatment approach for PNH is revolutionizing with approximately 16 drug molecules reported to be in the clinical trial and will have a positive impact on the growth of the PNH market during the forecast period.

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/59729

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

Paroxysmal nocturnal hemoglobinuria is an extremely rare disorder with a global incidence rate of 1.3 cases per 100,000 people, with approximately 20,000 people worldwide reported suffering from paroxysmal nocturnal hemoglobinuria. According to research findings from the International Bone Marrow Transplant Registry, hematopoietic stem cell transplantation from an allogeneic donor is the only cure for severe paroxysmal nocturnal hemoglobinuria. However, the high cost associated with this treatment protocol and the high mortality rate has reduced the popularity of this treatment regimen as a viable option. Since its approval in 2007, Soliris (eculizumab) is the only licensed drug prescribed for the treatment of PNH-associated hemolysis. Excellent drug efficacy and safety reported in clinical trial studies will increase the popularity of monoclonal antibodies as the most viable drug for the treatment of PNH.

For Any Query, Ask Our Expert at https://www.credenceresearch.com/inquiry-before-buying/59729

North America, with a share of 35%, is the global leader in the regional market for paroxysmal nocturnal hemoglobinuria. According to research findings of the National Institute of Health (NIH) in the United States, approximately 5,000 citizens suffer from paroxysmal nocturnal hemoglobinuria. Affordable reimbursement scenario and the domicile of key players such as Amgen, Inc., Alexion Pharmaceuticals, Roche, Regeneron Pharmaceuticals, etc. together are driving market growth in the North American region. Second, Europe is 28 per cent, mainly due to the high prevalence of paroxysmal nocturnal hemoglobinuria and the supportive regulatory environment provided by the European Medical Agency for the development of drugs used in the treatment of PNH. Asia Pacific holds 14.5 per cent of its market share mainly due to increasing public health awareness of the treatment of PNH and the development of healthcare infrastructure.

Amgen, Inc., Achillion Pharmaceuticals, Alexion Pharmaceuticals, Inc., Akari Therapeutics, Apellis Pharmaceuticals, Inc., CinnaGen, F.Hoffman-La Roche Ltd., Novartis AG, Ra Pharmaceuticals and Regeneron Pharmaceuticals are competing for a strong foothold in the paroxysmal nocturnal Hemoglobinuria market.

Key Market Movements:

  • Rising prevalence of paroxysmal nocturnal hemoglobinuria (PNH) in patients over 40 years of age.
  • Orphan disease designation awarded by healthcare agencies worldwide to fast track novel drug development for its treatment.
  • Strong product pipeline with drug molecules under investigation at different stages to revolutionize the PNH treatment protocol.

Key questions answered in this report

  • Which drug molecules are under clinical trial investigation and suggest to be strong drug pipeline during the forecast period?
  • What is the competitive scenario currently present among major players providing treatment options for PNH?
  • What is the disease etiology associated with paroxysmal nocturnal hemoglobinuria (PNH)?
  • Why is eculizumab the most popular drug for the treatment of PNH?
  • What is the market performance of PNH in both developed and developing regions worldwide?

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/59729

Leave a Reply

Your email address will not be published. Required fields are marked *